QURE Company Profile and Key Details

Q: Who are the executives of QURE?

Mr. Matthew Craig KapustaChief Executive Officer & Executive DirectorMs. Erin BoyerChief People & Culture OfficeMs. Maria E. CantorChief Corporation Affairs OfficerMr. Pierre CalozChief Operating OfficerDr. Jeannette Potts J.D., Ph.D.Chief Legal & Compliance OfficerMr. David CervenyChief Legal Officer, Gen. Counsel & Sec.Dr. Ricardo Dolmetsch Ph.D.Pres & Chief Scientific OfficerDr. Alexander E. Kuta Ph.D.Chief Regulatory OfficerDr. Tamara Tugal Ph.D., MBABus. Devel. DirectorMr. Richard Porter Ph.D.Chief Bus. OfficerMr. Christian KlemtChief Financial Officer, Principal Financial Officer & GM of Amsterdam SiteProf. Hugo KatusChairman of Scientific Advisory Board and Managing Director of UniQure-Germany

NASDAQ : QURE

uniQure NV

$44.39

-1.9-4.11%

At Close 4:00 PM

59.77

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

uniQure N.V. (QURE) stock declined over -4.10%, trading at $44.39 on NASDAQ, down from the previous close of $46.29. The stock opened at $46.30, fluctuating between $43.85 and $48.06 in the recent session.

Stock Snapshot

46.29

Prev. Close

2.8B

Market Cap

43.85

Day Low

-12.72

P/E Ratio

-3.49

EPS (TTM)

-3.2

Cash Flow per Share

46.3

Open

63.07M

Number of Shares

48.06

Day High

89.33%

Free Float in %

4.34

Book Value

2.8M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jun 22, 2026	46.29	48.06	43.84	44.39	2.8M
Jun 18, 2026	48.88	50.08	45.76	46.29	4.85M
Jun 17, 2026	43.55	49.70	42.50	48.16	19.63M
Jun 16, 2026	27.75	27.90	26.65	26.99	610.8K
Jun 15, 2026	27.75	28.50	27.26	27.87	1.09M
Jun 12, 2026	26.87	28.71	26.80	27.57	835.63K
Jun 11, 2026	26.69	27.69	26.01	26.82	1.31M
Jun 10, 2026	26.11	27.44	25.97	26.82	1.12M
Jun 09, 2026	27.33	27.50	25.65	26.46	1.18M
Jun 08, 2026	26.85	27.76	26.78	27.00	760.82K
Jun 05, 2026	27.63	28.19	26.30	26.45	1.45M
Jun 04, 2026	30.01	31.00	27.90	27.99	2.79M
Jun 03, 2026	27.02	30.45	26.90	29.88	2.87M
Jun 01, 2026	27.92	28.65	26.43	28.22	1.27M
May 29, 2026	28.75	29.48	27.59	28.53	3.55M
May 28, 2026	24.97	25.31	24.39	24.85	636.53K
May 27, 2026	25.15	25.74	24.83	25.17	516.56K
May 26, 2026	24.41	25.52	24.00	25.15	1.22M
May 22, 2026	24.95	25.54	24.16	24.19	670.56K
May 21, 2026	24.27	25.29	24.06	24.76	1.01M

Contact Details

Amsterdam, 1105 BP

United States

https://www.uniqure.com 312 024 06000

About Company

uniQure N.V. operates as a specialized gene therapy company, dedicated to pioneering therapeutic solutions for individuals grappling with severe genetic and other debilitating illnesses. The firm's most advanced project, Etranacogene dezaparvovec (designated as AMT-061), is currently progressing through a crucial Phase III pivotal trial, known as HOPE-B, targeting the treatment of hemophilia B. In addition to its flagship program, uniQure is actively developing several other candidates. This includes AMT-130, a gene therapy undergoing Phase I/II clinical assessment for Huntington's disease, and AMT-060, also in Phase I/II clinical trials for hemophilia B. The company's pipeline further extends to AMT-210 for Parkinson's disease, AMT-260 aimed at temporal lobe epilepsy, and AMT-161, which addresses amyotrophic lateral sclerosis. Furthermore, AMT-240 is an early-stage, preclinical product candidate focused on autosomal dominant Alzheimer's disease. Established in 1998, uniQure N.V. maintains its corporate headquarters in Amsterdam, Netherlands.

Stock Peers

ARGX

26.03+2.97%

argenx SE$903.75 REGN

2.56+0.42%

Regeneron Pharmaceuticals, Inc.$612.50 UTHR

1.70998+0.32%

United Therapeutics Corporation$538.30 MDGL

7.13+1.41%

Madrigal Pharmaceuticals, Inc.$512.88 VRTX

15.16+3.36%

Vertex Pharmaceuticals Incorporated$466.79 KRYS

-4.63-1.33%

Krystal Biotech, Inc.$343.43 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

21.08+7.47%

Praxis Precision Medicines, Inc.$303.39 ALNY

8.32+2.99%

Alnylam Pharmaceuticals, Inc.$286.41 LGND

-12.71-4.62%

Ligand Pharmaceuticals Incorporated$262.17

Frequently Asked Questions

What is the current uniQure N.V. (QURE) stock price?

uniQure N.V. (NASDAQ: QURE) stock price is $44.39 in the last trading session. During the trading session, QURE stock reached the peak price of $48.06 while $43.85 was the lowest point it dropped to. The percentage change in QURE stock occurred in the recent session was -4.1% while the dollar amount for the price change in QURE stock was - $1.90.

QURE's industry and sector of operation?

The NASDAQ listed QURE is part of Biotechnology industry that operates in the broader Healthcare sector. uniQure N.V. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of QURE?

Mr. Matthew Craig Kapusta
Chief Executive Officer & Executive Director
Ms. Erin Boyer
Chief People & Culture Office
Ms. Maria E. Cantor
Chief Corporation Affairs Officer
Mr. Pierre Caloz
Chief Operating Officer
Dr. Jeannette Potts J.D., Ph.D.
Chief Legal & Compliance Officer
Mr. David Cerveny
Chief Legal Officer, Gen. Counsel & Sec.
Dr. Ricardo Dolmetsch Ph.D.
Pres & Chief Scientific Officer
Dr. Alexander E. Kuta Ph.D.
Chief Regulatory Officer
Dr. Tamara Tugal Ph.D., MBA
Bus. Devel. Director
Mr. Richard Porter Ph.D.
Chief Bus. Officer
Mr. Christian Klemt
Chief Financial Officer, Principal Financial Officer & GM of Amsterdam Site
Prof. Hugo Katus
Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany

How QURE did perform over past 52-week?

QURE's closing price is 408.48% higher than its 52-week low of $8.73 where as its distance from 52-week high of $71.50 is -37.92%.

How many employees does QURE have?

Number of QURE employees currently stands at 209.

Link for QURE official website?

Official Website of QURE is: https://www.uniqure.com

How do I contact QURE?

QURE could be contacted at phone 312 024 06000 and can also be accessed through its website. QURE operates from Paasheuvelweg 25a, Amsterdam, 1105 BP, United States.

How many shares of QURE are traded daily?

QURE stock volume for the day was 2.8M shares. The average number of QURE shares traded daily for last 3 months was 2.03M.

What is the market cap of QURE currently?

The market value of QURE currently stands at $2.80B with its latest stock price at $44.39 and 63.07M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	209
Beta	1
Sales or Revenue	$15.84M
5Y Sales Change%	0.05%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	209
Beta	1
Sales or Revenue	$15.84M
5Y Sales Change%	0.05%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

QURE Company Profile and Key Details

uniQure NV

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Dividend & Fair Value

Company Overview

Earnings & Analyst Outlook

Valuation Metrics

Key Takeaways

Price Forecast & Outlook